This article on Epainassist.com has been reviewed by a medical professional , as well as checked for fact , to assure the readers the best potential truth .
We keep an eye on a strict editorial policy and we have a zero - tolerance insurance regarding any level of piracy . Our article are resourced from reputable on-line pageboy . This article may hold scientific character reference . The number in the digression ( 1 , 2 , 3 ) are clickable links to peer - reviewed scientific paper .
The feedback link “ Was this clause Helpful ” on this page can be used to describe content that is not precise , up - to - appointment or questionable in any manner .
This clause does not provide medical advice .
Myelofibrosis is a neoplastic clonal disorder of the haematogenic stem cells . It is characterized bybone marrowfibrosis , extramedullary hematopoiesis , anemia , splenomegaly , hepatomegalyand increased number of circulating blast cells . It can either be primary with no lie with etiology or secondary due to polycythemia vera and essential thrombocytosis . Although , the median time of survival for myelofibrosis patients is 5 years , there are wide-ranging rates of survival in case-by-case patients ranging from a year in some high risk patient role to over 10 years in depleted risk of exposure patients .
Is Myelofibrosis A Death Sentence?
Myelofibrosis can be a death condemnation for patients with mellow danger and greater disease severeness , but not for symptomless and low-pitched risk patients . The disease being quite rare , in addition to varied outcomes , the disease risk should be consider base on individual basis , severity of symptoms and other factor that might affect the disease outcome . This necessitates increase need for identifying patients who are at a greater peril for inadequate consequence and treat them consequently with allogeneic stem cell transplant .
The only remedial treatment for myelofibrosis is allogeneic stem cellphone transplant ; however , it is associated with high treatment related mortality rate that relate about 34 % . Since , the disease mostly presents in elderly patient , who are at a greater hazard of mortality colligate with allogeneic stem turn cadre transplantation and contraindication of it for these patients , most myelofibrosis sufferer are abstain from getting stem cell transplantation .
to begin with the prognosis scores were based on two factor , hemoglobin ( < 10 g / dl ) and leucocytes ( > 30 x 109 / l ) . However , this prognostic organization fail to identify higher endangerment patients in immature historic period group who could be make do with allogeneic stem cell transplantation . The shortcoming in this marking system led to a relatively new and superior prognostic scoring organisation that considered five factors to calculate the severeness of disease . These include , age > 65 years , hemoglobin < 10 g / dl , leucocytes > 25 x 109 / 50 , circulating crucify ≥1 % and built-in symptom . This prognostic scoring system , which had a average selection of 23 months for high endangerment group applicable at the time of diagnosing , was substandard in identifying patients with very high risk of disease event .
In a study of 370 affected role , the median natural selection of ≤12 months was learn in patient with the characteristics of platelets < 50 x 109 / 50 , pillory cellular phone in peripheral roue or pearl marrow ≥10 % and abnormality in chromosome 17 . The add advantage of this subject was that , the medical prognosis was good not only during initial diagnosis , but also at the time of follow up ; therefore , it was easier to determine the survival pace of patient with changing disease scenario . There was increased risk of demise if the platelets were below 50 x 109 / l and ≥10 % blast cells in circulation . In summation , anaemia was assort with pitiable prognosis with reduced selection and translation into acute myeloid leukemia.(1 ) ( 2 )
Although , chromosome 17 freakishness is extremely rarefied and found only in 2 % patients , it carry very poor forecast with medial survival of only 6 calendar month and higher risk ( > 40 % ) of transformation into leukemia . The pitiful forecast relate to chromosome 17 abnormality is associated with resistance to discourse in other diseases , such as multiple myeloma , chronic lymphocytic cancer of the blood and non - Hodgkin ’s lymphoma .
Therefore , it is very crucial to identify higher risk patient , specially those who are young and befitted for more fast-growing therapy , such as allogeneic theme cell organ transplant . Allogeneic stem cell transplantation has prove to be really curative in younger patients with greater disease costless remission time . Another medicine ruxolitinib ( Jakafi ) , which is JAK1 / JAK2 inhibitor is the only FDA sanction medication , has show ranking results in modifying the disease path of myelofibrosis patient who have poor prognosis . Other chemotherapeutic agents used in the management of myelofibrosis include interferon , cladribine , hydroxyurea , androgens , corticosteroids , thalidomide , and lenalidomide . Splenectomy is reserved for specific patient who fail to respond to chemotherapy and develop complications such as portal hypertension , progressive anemia , severe thrombopenia and persistent splenomegaly . intervention should always be done under the direction of an experienced hematologist.(3 )
reference :
Also Read :
